Clinical Trial Update: Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating magrolimab in combination with pembrolizumab for relapsed or refractory classical Hodgkin lymphoma. The study is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Magrolimab (magrolimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Stanford University | Conditions: Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING